Clinical trials: Systemic Lupus Erthematosus, open to volunteers
Systemic Lupus Erthematosus, Systemic Vasculitis
Rare AutoImmune SElf-management Programme Development
The rare autoimmune rheumatic diseases (RAIRDs) are life-long multi-system diseases that are life or organ threatening. RAIRDs can impair quality of life similar to chronic diseases such as heart failure.
- Conditions
- Systemic Lupus Erthematosus, Systemic Vasculitis, Inflammatory Myositis, Systemic Sclerosis (SSc)
- Trial name
- RAISE (NCT06642870)
- Testing
- Non-interventional study
- Where
- United Kingdom
- Volunteers
- 360 people
- Sponsor
- University of the West of England
Systemic Lupus Erthematosus
Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus Erythematosus
This randomized, double-blind, parallel-group, noninferiority clinical trial will evaluate the efficacy and safety of ivarmacitinib compared with oral prednisone in participants with mild-to-moderate active systemic lupus…
- Trial name
- NCT07814664
- Testing
- Ivarmacitinib Sulfate Tablets, Prednisone Acetate Tablets
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Lupus Erthematosus
Fibroblast Growth Factor 21 in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic disorder characterized by profound immune and metabolic disturbances. It emerges due to a complex interplay of genetic and environmental factors.
- Trial name
- NCT06842810
- Testing
- Serum FGF21 measurement by Enzyme- linked immunosorbent assay (ELISA)
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Assiut University
Systemic Lupus Erthematosus, Fatigue
Home-Based High-Intensity Interval Training in Systemic Lupus Erythematosus
Systemic lupus erythematosus, or SLE, is a chronic autoimmune disease that can cause persistent fatigue, muscle pain, reduced physical function, and impaired quality of life, even when the disease is otherwise clinically stable.
- Conditions
- Systemic Lupus Erthematosus, Fatigue, Exercise Training
- Trial name
- MIGHT-SLE (NCT07716462)
- Testing
- Personalized Home-Based High-Intensity Interval Training
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Autoimmune diseases refer to a common category of diseases caused by the immune system reacting to self-antigens, leading to tissue damage.
- Conditions
- Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06828042
- Testing
- anti-CD19 CAR T cell therapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University Third Hospital
Systemic Lupus Erthematosus (SLE)
Team-based Implementation of Hypertension Management in Childhood Lupus
The goal of this study is to compare the effectiveness of widely used implementation strategies to promote adherence to guideline-concordant evidence-based practices for monitoring and controlling blood pressure in patients with…
- Trial name
- ABOUT TIME (NCT07792733)
- Testing
- Health Navigator Engagement, Team Charter with Performance Monitoring, Pre-visit worksheet
- Volunteers
- 1,200 people
- Sponsor
- Boston Children's Hospital
Systemic Lupus Erthematosus (SLE)
2-HOBA in Systemic Lupus Erythematosus
This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE.
- Trial name
- NCT07225543
- Testing
- 2-HOBA acetate (2-Hydroxybenzlamine acetate)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Vanderbilt University Medical Center
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B cell mediated autoimmune disease.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07305116
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Systemic Lupus Erthematosus (SLE)
Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous
To study the effect of anti-inflammatory diet on clinical and biological outcomes in lupus
- Trial name
- NCT07713940
- Testing
- anti-inflammatory diet
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Diego
SLE, Lupus
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE). The main questions this study aims to answer are: 1.
- Conditions
- SLE, Lupus, Systemic Lupus Erthematosus, Systemic Lupus Erythematosus
- Trial name
- NCT06737380
- Testing
- Physical examination, Electrocardiogram, SF-36 questionnaire
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- LiveKidney.Bio
Systemic Lupus Erthematosus
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity.
- Trial name
- NCT07564596
- Testing
- Budoprutug
- Where
- 10 sites in China
- Volunteers
- 30 people
- Sponsor
- Climb Bio, Inc.
Rheumatic Diseases, Inflammatory Arthritis
The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions
The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate…
- Conditions
- Rheumatic Diseases, Inflammatory Arthritis, Systemic Lupus Erthematosus (SLE), Vasculitis
- Trial name
- NCT07278609
- Testing
- MedSafer deprescribing opportunity reports, EMPOWER brochures
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Systemic Lupus Erthematosus, Childhood-onset Systemic Lupus Erythematous
Gyrotonic Exercise in Lupus Adolescents Who Survived From Intensive Care
lupus adoelscented who recently survive from intenive care unit usually complain postintenive care unit syndrome in addition to stress, fatigue, low life quality, depression, low physical performance, low grip strenght, insomnia…
- Conditions
- Systemic Lupus Erthematosus, Childhood-onset Systemic Lupus Erythematous, Intensive Care Unit Survivors, Adolescents
- Trial name
- NCT07833020
- Testing
- Gryotonic exercise
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
- Trial name
- NCT07729995
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Luminary Therapeutics
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07507201
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Systemic Lupus Erthematosus (SLE)
KN5501 Cell Injection for Refractory SLE(CLEAR)
The goal of this clinical trial is to learn about the safety, pharmacokinetics and pharmacodynamics profile of KN5501 cell injection in adults with systemic lupus erythematosus(SLE).
- Trial name
- CLEAR (NCT07358988)
- Testing
- KN5501 cell injection
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Ruitherapeutics Co., LTD
Systemic Lupus Erthematosus, Auto Immune Disease
A Study of GR1803 in Systemic Lupus Erythematosus
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
- Trial name
- NCT07348055
- Testing
- GR1803 injection
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Systemic Lupus Erthematosus
Inducible Co-stimulator Gene With Systemic Lupus Erythematosus
The aim of this study is to investigate the association between ICOS gene polymorphism and susceptibility to systemic lupus erythematosus (SLE), as well as its impact on disease severity.
- Trial name
- ICOS/SLE (NCT07675837)
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- South Valley University
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219CX.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07586267
- Testing
- QT-219CX
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine